{"id":390065,"date":"2021-03-30T00:00:00","date_gmt":"2021-03-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0009-2020-biopharma-renal-cell-carcinoma-disease-landscape-and-forecast-g7-2020\/"},"modified":"2026-04-25T11:33:31","modified_gmt":"2026-04-25T11:33:31","slug":"dlsfon0009-2020-biopharma-renal-cell-carcinoma-disease-landscape-and-forecast-g7-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0009-2020-biopharma-renal-cell-carcinoma-disease-landscape-and-forecast-g7-2020\/","title":{"rendered":"Renal Cell Carcinoma | Disease Landscape and Forecast | G7 | 2020"},"content":{"rendered":"<p>Building on the success of the PD-1 inhibitor Opdivo (Bristol Myers Squibb \/ Ono Pharmaceutical) in the recurrent renal cell carcinoma setting, combination regimens, including Opdivo plus Yervoy, Keytruda (Merck &#038; Co.) plus Inlyta (Pfizer), Bavencio (Merck KGaA \/ Pfizer) plus Inlyta, are revolutionizing the treatment of advanced disease. Angiogenesis inhibitors such as Sutent (Pfizer), Votrient (Novartis), and Cabometyx (Exelixis \/ Ipsen) remain a key feature of first-line treatment. The entry and increased uptake of Cabometyx and Opdivo in this setting are beginning to shift Inlyta and Lenvima \/ Kisplyx (Eisai) plus Afinitor (Novartis) to later lines. Furthermore, following Sutent\u2019s approval for high-risk early-stage (stage I-III) patients, multiple immune checkpoint inhibitors are anticipated to transition to the early-stage setting. The renal cell carcinoma therapy market remains highly competitive and dynamic, but the developer of an efficacious therapy can expect to reap high commercial rewards.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>How are the early-stage and advanced or metastatic drug-treatable renal cell carcinoma populations defined, and how will drug-treatment rates evolve over the forecast period?<\/li>\n<li>What is the current treatment landscape for renal cell carcinoma, and what are interviewed experts\u2019 insights on current treatment options? What clinical needs remain unfulfilled?<\/li>\n<li>What is the outlook for key combination regimens in renal cell carcinoma? How will these combination regimens be differentiated, and which look the most promising?<\/li>\n<li>Which emerging therapies do we forecast to enter the renal cell carcinoma market? What uptake and sales are these therapies anticipated to secure?<\/li>\n<\/ul>\n<p><strong>Contents Highlights<\/strong><\/p>\n<p>Geographies: United States, EU5, Japan<\/p>\n<p>Primary Research: 19 country-specific interviews with thought-leading medical oncologists and urologists. Supported by survey data collected for this and other DRG research.<\/p>\n<p>Epidemiology: Diagnosed and recurrent incidence of renal cell carcinoma by country, segmented by drug-treatable and -treated early-stage and locally advanced or metastatic disease\u00a0and line of therapy.<\/p>\n<p>Forecast: 10-year, annualized, drug-level sales and patient share of key renal cell carcinoma therapies through 2029, segmented by brands\/generics and epidemiological subpopulations.<\/p>\n<p>Emerging Therapies: Phase III\/PR: 7 drugs; Phase II: 9 drugs; coverage of select preclinical and Phase I products.<\/p>\n<p><strong>Product Description<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast <\/em>provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390065","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-renal-cell-carcinoma","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390065","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390065\/revisions"}],"predecessor-version":[{"id":576429,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390065\/revisions\/576429"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390065"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}